Reprogramming of human fibroblasts into multipotent cells with a single ECM proteoglycan, fibromodulin

Biomaterials

Volumn 33, Issue 24, 2012, Pages 5821-5831

  Zheng, Zhong ^a   Jian, Jia ^a   Zhang, Xinli ^a   Zara, Janette N ^b   Yin, Wei ^a,c   Chiang, Michael ^a   Liu, Yi ^a,d   Wang, Joyce ^e   Pang, Shen ^a   Ting, Kang ^a   Soo, Chia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

Differentiation; Fibromodulin; Fibromodulin reprogrammed cells; FReP cells; Multipotent cells

Indexed keywords

BASIC RESEARCH; BONE TISSUE; CELL SOURCES; CELL-BASED; CLINICAL APPLICATION; CYCLIN-DEPENDENT KINASE INHIBITORS; EMBRYOID BODY; FIBROMODULIN; HUMAN FIBROBLAST; IN-VITRO; IN-VIVO; MULTIPOTENT CELLS; PLURIPOTENCY; PLURIPOTENT; PROTEOGLYCANS; REGENERATIVE MEDICINE; SINGLE MOLECULE; THERAPEUTIC APPLICATION;

CELL CULTURE; DIFFERENTIATION (CALCULUS); FIBROBLASTS; GENE THERAPY; RECOMBINANT PROTEINS; STEM CELLS; TISSUE; TISSUE ENGINEERING;

CELL ENGINEERING;

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FIBROMODULIN; PROTEOGLYCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE TISSUE; CELL DIFFERENTIATION; CELL DIVISION; CONTROLLED STUDY; DNA MODIFICATION; ECTODERM; EMBRYOID BODY; ENDODERM; FIBROBLAST; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MESODERM; MOUSE; MULTIPOTENT STEM CELL; MUSCLE REGENERATION; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE REGENERATION;

ADULT; BONE AND BONES; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFANT, NEWBORN; MUSCLE, SKELETAL; NUCLEAR REPROGRAMMING; PROTEOGLYCANS;

IPS;

EID: 84861757452     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.049     Document Type: Article

References (83)

1. Wilmut I., Schnieke A.E., McWhir J., Kind A.J., Campbell K.H. Viable offspring derived from fetal and adult mammalian cells. Nature 1997, 385:810-813.
2. Wakayama T., Perry A.C., Zuccotti M., Johnson K.R., Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature 1998, 394:369-374.
3. Byrne J.A., Pedersen D.A., Clepper L.L., Nelson M., Sanger W.G., Gokhale S., et al. Producing primate embryonic stem cells by somatic cell nuclear transfer. Nature 2007, 450:497-502.
4. Tada M., Takahama Y., Abe K., Nakatsuji N., Tada T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol 2001, 11:1553-1558.
5. Cowan C.A., Atienza J., Melton D.A., Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005, 309:1369-1373.
6. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
7. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
8. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
9. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007, 448:318-324.
10. Maherali N., Sridharan R., Xie W., Utikal J., Eminli S., Arnold K., et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 2007, 1:55-70.
11. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
12. Walia B., Satija N., Tripathi R.P., Gangenahalli G.U. Induced pluripotent stem cells: fundamentals and applications of the reprogramming process and its ramifications on regenerative medicine. Stem Cell Rev Rep 2012, 8:100-115.
13. Miura K., Okada Y., Aoi T., Okada A., Takahashi K., Okita K., et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009, 27:743-745.
14. Zheng Z., Nguyen C., Zhang X., Khorasani H., Wang J.Z., Zara J.N., et al. Delayed wound closure in fibromodulin-deficient mice is associated with increased TGF-beta3 signaling. J Invest Dermatol 2011, 131:769-778.
15. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 2008, 105:2883-2888.
16. Hotta A., Cheung A.Y., Farra N., Vijayaragavan K., Seguin C.A., Draper J.S., et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods 2009, 6:370-376.
17. Roy N.S., Nakano T., Xuing L., Kang J., Nedergaard M., Goldman S.A. Enhancer-specified GFP-based FACS purification of human spinal motor neurons from embryonic stem cells. Exp Neurol 2005, 196:224-234.
18. Nizzardo M., Simone C., Falcone M., Locatelli F., Riboldi G., Comi G.P., et al. Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. Cell Mol Life Sci 2010, 67:3837-3847.
19. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26:1269-1275.
20. D'Amour K.A., Agulnick A.D., Eliazer S., Kelly O.G., Kroon E., Baetge E.E. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol 2005, 23:1534-1541.
21. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009, 104:e30-41.
22. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
23. Zhang X., Peault B., Chen W., Li W., Corselli M., James A.W., et al. The Nell-1 growth factor stimulates bone formation by purified human perivascular cells. Tissue Eng Part A 2011, 17:2497-2509.
24. Ausubel F.M., Brent R., Kingston R.E., More D.D., Seidman J.G., Smith J.A., et al. Short protocols in molecular biology 1999, Wiley John & Sons Inc., New York. 4th ed.
25. Villa-Diaz L.G., Nandivada H., Ding J., Nogueira-de-Souza N.C., Krebsbach P.H., O'Shea K.S., et al. Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nat Biotechnol 2010, 28:581-583.
26. Papp B., Plath K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Res 2011, 21:486-501.
27. Theunissen T.W., Silva J.C.R. Switching on pluripotency: a perspective on the biological requirement of Nanog. Philos Trans R Soc Lond B Biol Sci 2011, 366:2222-2229.
28. Beattie G.M., Lopez A.D., Bucay N., Hinton A., Firpo M.T., King C.C., et al. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells 2005, 23:489-495.
29. Xu R.H., Sampsell-Barron T.L., Gu F., Root S., Peck R.M., Pan G., et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 2008, 3:196-206.
30. Besser D. Expression of nodal, lefty-a, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad2/3. J Biol Chem 2004, 279:45076-45084.
31. James D., Levine A.J., Besser D., Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005, 132:1273-1282.
32. Vallier L., Alexander M., Pedersen R.A. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 2005, 118:4495-4509.
33. Xiao L., Yuan X., Sharkis S.J. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells 2006, 24:1476-1486.
34. Fujita T., Azuma Y., Fukuyama R., Hattori Y., Yoshida C., Koida M., et al. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166:85-95.
35. Shen J., Hovhannisyan H., Lian J.B., Montecino M.A., Stein G.S., Stein J.L., et al. Transcriptional induction of the osteocalcin gene during osteoblast differentiation involves acetylation of histones h3 and h4. Mol Endocrinol 2003, 17:743-756.
36. Yan Z., Choi S., Liu X., Zhang M., Schageman J.J., Lee S.Y., et al. Highly coordinated gene regulation in mouse skeletal muscle regeneration. J Biol Chem 2003, 278:8826-8836.
37. Ruiz S., Panopoulos A.D., Herrerias A., Bissig K.D., Lutz M., Berggren W.T., et al. A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Curr Biol 2011, 21:45-52.
38. Schmidt E.V. The role of c-myc in regulation of translation initiation. Oncogene 2004, 23:3217-3221.
39. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008, 26:101-106.
40. Gold L., Lecanda J. Mechanisms of cell cycle regulation by TGF-β disabled in cancer. Transforming growth factor-β in cancer therapy 2008, Humana Press Inc., Totowa, NJ. S.B. Jakowlew (Ed.).
41. Li J.Y., Christophersen N.S., Hall V., Soulet D., Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci 2008, 31:146-153.
42. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007, 1:39-49.
43. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008, 105:5856-5861.
44. Yamanaka S. A fresh look at iPS cells. Cell 2009, 137:13-17.
45. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
46. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
47. Barrilleaux B., Knoepfler P.S. Inducing iPSCs to escape the dish. Cell Stem Cell 2011, 9:103-111.
48. Ellis J., Bruneau B.G., Keller G., Lemischka I.R., Nagy A., Rossant J., et al. Alternative induced pluripotent stem cell characterization criteria for in vitro applications. Cell Stem Cell 2009, 4:198-199.
49. Fox J.L. Human iPSC and ESC translation potential debated. Nat Biotechnol 2011, 29:375-376.
50. Zhou Q., Brown J., Kanarek A., Rajagopal J., Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008, 455:627-632.
51. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Sudhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041.
52. Taranger C.K., Noer A., Sorensen A.L., Hakelien A.M., Boquest A.C., Collas P. Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. Mol Biol Cell 2005, 16:5719-5735.
53. Hansis C., Barreto G., Maltry N., Niehrs C. Nuclear reprogramming of human somatic cells by xenopus egg extract requires BRG1. Curr Biol 2004, 14:1475-1480.
54. Zhu X.Q., Pan X.H., Wang W., Chen Q., Pang R.Q., Cai X.M., et al. Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. Biomaterials 2010, 31:2779-2787.
55. Ng V.Y., Choo A.B.H. iPS and ES cells: do both roads lead to Rome?. Open Stem Cell J 2010, 2:8-17.
56. Cavaleri F., Scholer H.R. Nanog: a new recruit to the embryonic stem cell orchestra. Cell 2003, 113:551-552.
57. Chambers I., Colby D., Robertson M., Nichols J., Lee S., Tweedie S., et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113:643-655.
58. Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K., et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642.
59. Boyer L.A., Lee T.I., Cole M.F., Johnstone S.E., Levine S.S., Zucker J.P., et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956.
60. Loh Y.H., Wu Q., Chew J.L., Vega V.B., Zhang W., Chen X., et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006, 38:431-440.
61. Kim J., Chu J., Shen X., Wang J., Orkin S.H. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008, 132:1049-1061.
62. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
63. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
64. Woodbury D., Reynolds K., Black I.B. Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. J Neurosci Res 2002, 69:908-917.
65. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7:211-228.
66. Bi Y., Ehirchiou D., Kilts T.M., Inkson C.A., Embree M.C., Sonoyama W., et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007, 13:1219-1227.
67. Radtke S., Horn P.A. Cells, niche, fate: meeting report on the 6th International Meeting of the stem cell network North Rhine Westphalia. Cell Reprogram 2011, 13:381-384.
68. Eshghi S., Schaffer D.V. Engineering microenvironments to control stem cell fate and function. StemBook 2008, Harvard Stem Cell Institute, Cambridge, MA. The Stem Cell Research Community (Ed.).
69. Zheng Z., Nguyen K., Wang J.Z., Zhang X., Ting K., Soo C. Differential expression of transforming growth factor (TGF)-β s and TGF-β receptors during skin wound healing in adult mice with fibromodulin (FMOD) deficiency. Wound Repair Regen 2008, 16. p. A28-A.
70. Khorasani H., Zheng Z., Nguyen C., Zara J., Zhang X.L., Wang J.C., et al. A quantitative approach to scar analysis. Am J Pathol 2011, 178:621-628.
71. Sjoberg A., Onnerfjord P., Morgelin M., Heinegard D., Blom A.M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem 2005, 280:32301-32308.
72. Sjoberg A.P., Manderson G.A., Morgelin M., Day A.J., Heinegard D., Blom A.M. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 2009, 46:830-839.
73. Mayr C., Bund D., Schlee M., Moosmann A., Kofler D.M., Hallek M., et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 2005, 105:1566-1573.
74. Svensson L., Aszodi A., Reinholt F.P., Fassler R., Heinegard D., Oldberg A. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J Biol Chem 1999, 274:9636-9647.
75. Oldberg A., Kalamajski S., Salnikov A.V., Stuhr L., Morgelin M., Reed R.K., et al. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci U S A 2007, 104:13966-13971.
76. Ichida J.K., Blanchard J., Lam K., Son E.Y., Chung J.E., Egli D., et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009, 5:491-503.
77. Theunissen T.W., van Oosten A.L., Castelo-Branco G., Hall J., Smith A., Silva J.C.R. Nanog overcomes reprogramming barriers and induces pluripotency in minimal conditions. Curr Biol 2011, 21:65-71.
78. Lin T.X., Ambasudhan R., Yuan X., Li W.L., Hilcove S., Abujarour R., et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009, 6. p 805-U24.
79. Ruscetti F.W., Bartelmez S.H. Cell cycle control and check points in hematopoietic stem cells. Handbook of stem cells 2004, Elsevier Academic Press, San Diego. R. Lanza, J. Gearhart, B. Hogan, D. Melton, R. Pedersen, J. Thomson (Eds.).
80. Kippin T.E., Martens D.J., van der Kooy D. p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev 2005, 19:756-767.
81. Cheng T., Rodrigues N., Shen H., Yang Y., Dombkowski D., Sykes M., et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000, 287:1804-1808.
82. Cheng T. Cell cycle inhibitors in normal and tumor stem cells. Oncogene 2004, 23:7256-7266.
83. Bilousova G., Jun D.H., King K.B., De Langhe S., Chick W.S., Torchia E.C., et al. Osteoblasts derived from induced pluripotent stem cells form calcified structures in scaffolds both in vitro and in vivo. Stem Cells 2011, 29:206-216.